Loading organizations...
Based in Philadelphia, Pennsylvania, Allevi develops desktop 3D bioprinters, proprietary bioinks, and specialized software for tissue engineering, disease modeling, and regenerative medicine research. The company operates a business-to-business model selling hardware and consumables to pharmaceutical companies, biotechnology firms, and academic institutions, with its desktop bioprinters currently utilized in hundreds of medical research labs globally. In May 2021, the enterprise was acquired by publicly traded manufacturing company 3D Systems to expand its regenerative medicine initiatives and scale its laboratory footprint. Prior to this acquisition, the firm partnered with aerospace manufacturer Made In Space in 2020 to develop a specialized bioprinter designed specifically for microgravity operations aboard the International Space Station. Originally operating under the initial name BioBots before executing a comprehensive corporate rebranding in 2017, Allevi was founded in 2014 by Ricky Solorzano and Danny Cabrera.
Allevi has raised $3.0M across 2 funding rounds.
Allevi has raised $3.0M in total across 2 funding rounds.
Allevi has raised $3.0M across 2 funding rounds. Most recently, it raised $2.0M Series A in October 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2019 | $2M Series A | — | 1435 Capital Management, Aglae Ventures, Somesh Surapureddi, DFJ, E1 Ventures, Family Office, Future Ventures, Gigafund, GoAhead Ventures, Lakeside Capital, Litquidity Ventures, Long Journey Ventures, Malex Enterprises, Outliers Fund, Partners Resolute, Social Capital, Space Capital, Starbridge Venture Capital, UpHonest Capital, Adeel Hussain, Fanny Surjana, Ishani Patel, Louis Beryl, Mattia Astori, Priyank Chandra, Rashaun Williams, Richard Cooperstein, Scott Banister, Shane Neman, Siddharth Singhal, TIM Ringel, Vikas Sabnani | Announced |
| Sep 1, 2015 | $1M Seed | — | BioAdvance | Announced |
Allevi has raised $3.0M in total across 2 funding rounds.
Allevi's investors include 1435 Capital Management, Aglae Ventures, Somesh Surapureddi, DFJ, E1 Ventures, Family Office, Future Ventures, Gigafund, GoAhead Ventures, Lakeside Capital, Litquidity Ventures, Long Journey Ventures.
Allevi is a bioprinting technology company that develops desktop 3D bioprinters, bioinks, and related software to enable researchers to design and engineer 3D tissues.[1][2][3] Founded in 2014 and acquired by 3D Systems in 2021, it serves academic labs, pharmaceutical companies, and regenerative medicine researchers worldwide by addressing challenges in tissue engineering, drug testing, disease modeling, and organ-on-a-chip applications.[1][4][5] Its tools simplify bioprinting for applications like curing diseases, eliminating organ shortages, and accelerating drug discovery, with products trusted in hundreds of labs despite discontinuing bioprinter production in July 2023.[1][5]
Allevi's growth includes rebranding from BioBots and integration into 3D Systems' bioprinting portfolio, headquartered in Philadelphia with a focus on versatile, user-friendly hardware like patented CORE extruders for high cell viability across bioinks.[3][4][5]
Allevi was founded in 2014 in Philadelphia, Pennsylvania, initially as BioBots, with a mission to democratize 3D bioprinting by creating the first commercially available desktop bioprinters.[1][2][3] The founders aimed to empower researchers to engineer living tissues affordably, emerging from the need for accessible tools in regenerative medicine and tissue engineering.[2][4]
A pivotal moment came in 2021 when Allevi joined 3D Systems, enhancing its capabilities in advanced bioprinting and expanding its global reach to leading researchers and industry players.[1][3] Early traction built through community-inspired innovations, positioning it as a key player in solving humanity's toughest medical challenges like organ shortages and drug testing.[1][5]
Allevi's standout features center on accessibility and performance in bioprinting:
(Note: Bioprinter production ended in 2023, but bioinks and support continue via 3D Systems.[5])
Allevi rides the 3D bioprinting wave in regenerative medicine, enabling *in vitro* models that mimic *in vivo* tissues to accelerate drug screening, cancer research, vaccine development, and personalized medicine.[1][4][5] Its timing aligns with surging demand for organ-on-a-chip and disease modeling amid organ shortages and rising R&D costs in pharma, where traditional 2D models fall short.[5]
Market forces like advancements in biomaterials and AI-driven design favor Allevi, influencing the ecosystem by lowering barriers for researchers—shifting bioprinting from elite labs to widespread use and spurring startups in tissue engineering.[2][4] As part of 3D Systems, it amplifies industry consolidation, pushing scalable solutions for clinical translation.[1][3]
Allevi's legacy lies in pioneering accessible bioprinting, but post-2023 discontinuation signals a pivot to bioinks and software under 3D Systems, potentially integrating with broader additive manufacturing.[1][5] Next steps likely emphasize sustained materials supply and community tools amid trends like AI-optimized tissues and hybrid organ printing.
Rising investments in regenerative tech—projected to grow with personalized medicine—could evolve its influence toward enabling full organs, tying back to its founding vision of building with life to cure diseases and end transplant waits.[1][4]
